Schisanlignone D exhibits significant anti-inflammatory and hepatoprotective properties, making it a compound of interest in the development of liver-protective agents. It has been studied for its ability to reduce liver enzyme levels and mitigate oxidative stress in hepatic tissues, suggesting potential use in treating liver diseases such as hepatitis and drug-induced liver injury. Additionally, it shows inhibitory activity against certain cancer cell lines, particularly in liver and breast cancer models, indicating possible application in oncology research. Its bioactive profile supports further exploration in pharmaceuticals targeting inflammation-related disorders and liver health.